All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PBT2
Therapeutic Area: Infections and Infectious Diseases Product Name: PBT2
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Alterity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 21, 2020
Details:
The licensed technology combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. This is an opportunity for Alterity to further leverage its investment in PBT2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMM-124E
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Monash University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 15, 2020
Details:
A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron’s marketed products (IMM-124E).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recce 327
Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
RECCE® 327 showed encouraging inhibition and is advancing to Stage 1b (confirmatory in-vitro testing and a cytotoxicity assessment), underway in near weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The novel product, INNA-051, being developed by Australian biotech company, Ena Respiratory, reduced viral replication by up to 96 percent in a gold-standard animal study led by Public Health England.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recce 327
Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Australian Government Department of Industry, Science, Energy and Resources
Deal Size: $0.02 million Upfront Cash: Undisclosed
Deal Type: Funding September 01, 2020
Details:
The grant will be directed towards project costs associated with assessing RECCE® 327 in the SARS-CoV-2 Antiviral Screening Program and is subject to performance based milestones.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RECCE 435
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 435
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
New RECCE® 435 oral showed dose-dependent and efficacy against Helicobacter pylori (H. pylori) bacteria isolated from a patient with a duodenal ulcer compared to control vehicle in independent study model in rats.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMM-124E
Therapeutic Area: Infections and Infectious Diseases Product Name: IMM-124E
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
IMM-124E, the technology platform used to manufacture the company’s over-the-counter gastrointestinal & digestive health immune supplements Travelan® and Protectyn® has demonstrated neutralizing activity against SARS-CoV-2 in laboratory studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Atossa Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 22, 2020
Details:
The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recce 327
Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: CSIRO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
Details:
RECCE® 327 and New RECCE® 529 compounds were selected for their unique mechanisms of action against hyper-mutation, as indicated on bacteria and viruses (respectively).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pixatimod
Therapeutic Area: Infections and Infectious Diseases Product Name: PG545
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020
Details:
Zucero’s clinical-stage drug candidate pixatimod demonstrates potent antiviral activity against the COVID-19 virus in laboratory studies.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
